Cancer 20immunotherapy 20breakthrough 202013

Savoy Pharmaceuticals

Bringing less harmful and more effective therapies to cancer patients. A monoclonal antibody therapy shown in preclinical tests as 98.9% effective in cancers.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Salt Lake City, UT, USA
  • Currency USD
  • Founded December 2004
  • Employees 3
  • Website

Company Summary

Savoy Pharmaceuticals is an emerging therapeutic company in the field of Immunotherapy. Savoy's first target is their patented novel tumor marker found on the surface of several cancer types s well as viruses. The company is preparing the IND application for Phase I clinical trials for liver and pancreatic cancers. Comprised of a team of Dr.'s and MBA's with backgrounds from UCLA, University of Rochester, BYU, MD Anderson, Roche, and Genentech.


  • Default avatar
    Nathaniel Lallatin, MBA

    Previously he co-founded a medical diagnostic company, Celtic Biotech, which he ran for two years before turning his focus to therapeutics. Nathaniel worked for a merchant bank, Latona Associates, where he led the scientific arm of Fisher Scientific’s acquisition of PSS World Medical for $840M, and its acquisition of Cole-Parmer Instrument Company for $205M. Mr. Lallatin previously worked in the medical device industry where he worked with Roche

  • Default avatar
    Gerald Lallatin, MBA, JD
    Board Director

    Mr. Lallatin was Chief Financial Officer and Senior Vice President of Idaho Bank and Trust; and Chief Financial Officer of IB&T Corp. where in addition to his financial responsibilities; he helped negotiate acquisitions of other banks and the sale of IB&T to Key Bank. He was also a CPA with the firm of Ernst & Ernst specializing in audits and management consulting for regional corporations. At the law firm of Richards, Brandt, Miller & Nelson,

  • Default avatar
    Dr. Asim Dasgupta, Ph.D
    Scientific Advisor

    A virologist and molecular biologist who has served on the UCLA School of Medicine faculty in 1981. Dr. Dasgupta earned his B.S. in Chemistry and M.S. Biochemistry from Calcutta University, India, followed by a Ph.D. degree in Chemistry/Biochemistry from the University of Nebraska-Lincoln. Dr. Dasgupta received the prestigious American Cancer Society Faculty Research award as well as the NIH Career Development Award.

  • Default avatar
    Dr. Michael Rosenblum, Ph.D
    Scientific Advisor

    Professor of Medicine at the M.D. Anderson Cancer Center. Working in pharmacology of biological agents, particularly proteins, which are capable of targeting selected cells and developing tumor cell-targeted cytotoxic agents.
    Additionally, researching tumor cell-signaling events and employing signaling strategies to achieve therapeutic goals.

  • Default avatar
    Dave Griffiths
    Business Advisor

    Mr. David Griffiths is the owner of The Consultants LLC and Treasurer of Sunset Presbyterian Church., Inc. Mr Griffiths has 18 years management experience and 3 years administration experience prior to becoming an entrepreneur. Mr Griffiths has founded 3 businesses and sold 1 since 2003. He currently focuses his efforts on teaching financial seminars and training businesses to create their own programs

  • Default avatar
    Mathew Lallatin
    Business Advisor

    Mr. Matthew Lallatin is the Chief Financial Officer of CHIPS, Inc. Mr. Lallatin has 18 years’ experience in all aspects of corporate finance in multiple industries and organizations ranging from start-up to $150 Billion in sales. Matthew earned his MBA from Brigham Young University.


  • Default avatar
    Dr. Bart Chapman
    Scientific Advisory Board